Patents by Inventor Brian Berquist

Brian Berquist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD-25 ANTIBODY
    Publication number: 20250034267
    Abstract: Materials and methods for using polypeptides containing fragments and variants of the antibody(ies) or portion(s) thereof that bind CD25 to treat cancer alone or in combination with other anti-neoplastic agents.
    Type: Application
    Filed: September 4, 2024
    Publication date: January 30, 2025
    Inventors: Dillon Phan, Martin Brenner, Brian Berquist, Peter Kipp, Tam Phuong, Kevin Babilonia, Tom Hsu, Lufei Hu, James Talmage Taylor, JR., Cory Schwartz
  • Anti-CD-25 antibody
    Patent number: 12129302
    Abstract: Materials and methods for using polypeptides containing fragments and variants of the antibody(ies) or portion(s) thereof that bind CD25 to treat cancer alone or in combination with other anti-neoplastic agents.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: October 29, 2024
    Assignee: iBio, Inc.
    Inventors: Dillon Phan, Martin Brenner, Brian Berquist, Peter Kipp, Tam Phuong, Kevin Babilonia, Tom Hsu, Lufei Hu, James Talmage Taylor, Jr., Cory Schwartz
  • ANTI-CD-25 ANTIBODY
    Publication number: 20230159646
    Abstract: Materials and methods for using polypeptides containing fragments and variants of the antibody(ies) or portion(s) thereof that bind CD25 to treat cancer alone or in combination with other anti-neoplastic agents.
    Type: Application
    Filed: August 22, 2022
    Publication date: May 25, 2023
    Inventors: Dillon Phan, Martin Brenner, Brian Berquist, Peter Kipp, Tam Phuong, Kevin Babilonia, Tom Hsu, Lufei Hu, James Talmage Taylor, JR., Cory Schwartz
  • SARS-COV-2 SUBUNIT AND VARIANT VACCINES
    Publication number: 20220372080
    Abstract: The present invention includes an immunogenic protein, constructs, vectors, and methods of making, comprising at least 90% amino acid identity to at least one antigenic peptide selected from: a coronavirus Receptor Binding Domain (RBD), coronavirus a Receptor Binding Motif (RBM) of a coronavirus spike protein, a coronavirus spike protein N-terminus, a nucleocapsid protein, one or more T cell epitopes from a coronavirus spike protein, or one or more T cell epitopes from a coronavirus nucleocapsid protein, or combination thereof. In one example, the at least one antigenic peptide is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the carrier protein or peptide tag.
    Type: Application
    Filed: April 21, 2022
    Publication date: November 24, 2022
    Inventors: Peter Kipp, Brian Berquist, Sreenath Palle